Giancarlo Parenti
Giancarlo Parenti is an expert in Genetics at Federico II University Hospital (Italy). As of October 2026, ScienceLeadR ranks Giancarlo Parenti in the top 1% of experts worldwide for Metabolism, Inborn Errors and Brain Diseases, Metabolic. Giancarlo Parenti has authored 407 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 1,094 (community average: 125). How the SLR is computed.
LeadR Profile
Genetics
Subspecialties: Neurology - Immunology - Pediatrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1985 - 2026
Number : 407
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| S-Nitrosylation of glycogen phosphorylase regulates nuclear glycogenolysis and is impaired in metabolic liver disorders. PMID 42826186 — cytosol, glycogen, phosphorylases, liver, glycogen phosphorylase | Sci Adv | 2026 | 0 |
| TRPML1 agonists synergize with enzyme replacement therapy in fibroblasts from Pompe disease patients. PMID 42277847 — cells, genes, biomedical research, cell membrane, enzymes, glycogen storage disease type ii, fibroblasts, enzyme replacement therapy, therapeutics, membranes, plasma | J Transl Med | 2026 | 0 |
| Telethon Undiagnosed Disease Program: Structured approach to solving rare childhood-onset genetic diseases. PMID 42016445 — undiagnosed diseases, diagnosis, therapeutics, genetic diseases, inborn | Genet Med Open | 2026 | 0 |
| Uncovering mitochondrial defects in photoreceptors opens therapeutic opportunities for Stargardt disease. PMID 41984830 — stargardt disease, phenotype, mitochondria, photoreceptor cells, therapeutics, retinaldehyde | Proc Natl Acad Sci U S A | 2026 | 0 |
| Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease. PMID 41769220 — cells, muscles, blood, glucosidases, enzymes, glycogen storage disease type ii, therapeutics, tissues | Ther Adv Rare Dis | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
LeadR Networks
Main global connection map